top of page

Mar 13, 2023

PsyBio Therapeutics Founder Wins Best Pitch at Investment Summit

Jan 17, 2023

A PsyBio Therapeutics Corp. (CVE:PSYB) insider increased their holdings last year

Jan 13, 2023

PsyBio Announces Closing of Second Tranche of Private Placement

Jan 10, 2023

PsyBio Announces Appointment of Ian Wisenberg to Board of Directors

Jan 5, 2023

PsyBio Announces Closing of First Tranche of Private Placement Led by the Chairman and Chief Executive Officer with Participation from the Entire Board of Directors and Management Team and Provides Corporate Update

Dec 8, 2022

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

Dec 6, 2022

PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio

Dec 1, 2022

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

Nov 29, 2022

PsyBio Therapeutics Reports Third Quarter 2022 Financial Results

Oct 11, 2022

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

Sep 19, 2022

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Sep 7, 2022

PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

bottom of page